Similar articles

• LHRH analogues and breast cancer.

  Korkut E, Comaru-Schally AM, Schally AV, Plowman PN. Korkut E, et al. Br J Cancer. 1991 Dec;64(6):1190. doi: 10.1038/bjc.1991.490. Br J Cancer. 1991. PMID: 1764388 Free PMC article. No abstract available.
• Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.

  Conte B, Poggio F, Del Mastro L. Conte B, et al. Expert Opin Pharmacother. 2017 Sep;18(13):1357-1362. doi: 10.1080/14656566.2017.1363181. Epub 2017 Aug 10. Expert Opin Pharmacother. 2017. PMID: 28764603 Review.
• Clinical use of GnRH analogues.

  Kiesel LA, Rody A, Greb RR, Szilágyi A. Kiesel LA, et al. Clin Endocrinol (Oxf). 2002 Jun;56(6):677-87. doi: 10.1046/j.1365-2265.2002.01291.x. Clin Endocrinol (Oxf). 2002. PMID: 12072036 Review. No abstract available.
• The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer.

  Rossi L, Pagani O. Rossi L, et al. J Womens Health (Larchmt). 2018 Apr;27(4):466-475. doi: 10.1089/jwh.2017.6355. Epub 2017 Sep 19. J Womens Health (Larchmt). 2018. PMID: 28926289
• Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

  Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Klijn JG, et al. J Clin Oncol. 2001 Jan 15;19(2):343-53. doi: 10.1200/JCO.2001.19.2.343. J Clin Oncol. 2001. PMID: 11208825